1. An observational study on the effects of nadroparin-based and citrate-based continuous venovenous hemofiltration on calcium metabolism.
- Author
-
van der Voort PH, Postma SR, Kingma WP, Boerma EC, de Heide LJ, and Bakker AJ
- Subjects
- Acute Kidney Injury blood, Aged, Anticoagulants adverse effects, Calcium administration & dosage, Calcium pharmacokinetics, Calcium therapeutic use, Calcium Citrate metabolism, Chelating Agents therapeutic use, Citrates therapeutic use, Critical Care methods, Critical Illness therapy, Female, Hemorrhage chemically induced, Hemorrhage prevention & control, Humans, Hyperparathyroidism, Secondary blood, Hypocalcemia chemically induced, Hypocalcemia etiology, Hypocalcemia prevention & control, Male, Middle Aged, Nadroparin adverse effects, Parathyroid Hormone blood, Prospective Studies, Sodium Citrate, Vitamin D analogs & derivatives, Vitamin D blood, Acute Kidney Injury therapy, Anticoagulants therapeutic use, Calcium blood, Chelating Agents adverse effects, Citrates adverse effects, Hemofiltration methods, Hyperparathyroidism, Secondary chemically induced, Nadroparin therapeutic use
- Abstract
Background: To study calcium homeostasis during citrate-based compared to nadroparin-based CVVH in critically-ill patients with acute renal failure., Methods: 11 patients were observed during citrate anticoagulation, 9 with nadroparin and 10 controls. Citrate was chosen for patients with active or at risk for bleeding., Results: The controls had, at 24 h, a median serum iCa of 1.1 mmol/l, the citrate group 0.87 mmol/l and the nadroparin group 1.1 mmol/l (citrate vs. control p = 0.001, citrate vs. nadroparin p = 0.002). At 48 h, iCa was not significantly different anymore. Ca balance was negative for the citrate group in contrast to the nadroparin group (p = 0.012). Median serum PTH was higher (30.0 pmol/l vs. 6.5 pmol/l, p = 0.003) in the citrate group., Conclusion: With a relative low target-serum-iCa (0.8-0.9 mmol/l) citrate CVVH-treated patients had a negative daily calcium balance and a temporarily lower iCa level resulting in an enhanced PTH response in comparison to nadroparin., (Copyright 2007 S. Karger AG, Basel.)
- Published
- 2007
- Full Text
- View/download PDF